Balaji Gowrivel Vijayakumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Balaji Gowrivel Vijayakumar has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Deepthi Ramesh
Department of Chemistry Pondicherry University Puducherry India
6 shared publications - Tharanikkarasu Kannan
Department of Chemistry Pondicherry University Puducherry India
6 shared publications Aiswarya Sethumadhavan
Department of Microbiology, Pondicherry University, Kalapet, Puducherry-605014, India
3 shared publicationsMaheswaran Mani
Department of Microbiology, Pondicherry University, Kalapet, Puducherry-605014, India
3 shared publicationsAmaresh Kumar Mohanty
Department of Bioinformatics, Pondicherry University, Kalapet, Puducherry-605014, India
1 shared publicationAnirban De
Department of Chemistry, Pondicherry University, Kalapet, Puducherry-605014, India
1 shared publication
Latest Publications
- Open Access
- 7 June 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (27) , 17466-17480
Uracil derivatives as HIV-1 capsid protein inhibitors: design, in silico, in vitro and cytotoxicity studies
A series of novel uracil derivatives such as bispyrimidine dione and tetrapyrimidine dione derivatives were designed based on the existing four-point pharmacophore model as effective HIV capsid protein inhibitors. The compounds were initially docked with an HIV capsid protein monomer to rationalize the ideas of design and to find the potential binding modes. The successful design and computational studies led to the synthesis of bispyrimidine dione and tetrapyrimidine dione derivatives from uracil and aromatic aldehydes in the presence of HCl using novel methodology. The in vitro evaluation in HIV p24 assay revealed five potential uracil derivatives with IC50 values ranging from 191.5 μg ml−1 to 62.5 μg ml−1. The meta-chloro substituted uracil compound 9a showed promising activity with an IC50 value of 62.5 μg ml−1 which is well correlated with the computational studies. As expected, all the active compounds were noncytotoxic in BA/F3 and Mo7e cell lines highlighting the thoughtful design. The structure activity relationship indicates the position priority and lower log P values as the possible cause of inhibitory potential of the uracil compounds.
- 7 June 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (27) , 17466-17480
Open AccessUracil derivatives as HIV-1 capsid protein inhibitors: design, in silico, in vitro and cytotoxicity studies
A series of novel uracil derivatives such as bispyrimidine dione and tetrapyrimidine dione derivatives were designed based on the existing four-point pharmacophore model as effective HIV capsid protein inhibitors. The compounds were initially docked with an HIV capsid protein monomer to rationalize the ideas of design and to find the potential binding modes. The successful design and computational studies led to the synthesis of bispyrimidine dione and tetrapyrimidine dione derivatives from uracil and aromatic aldehydes in the presence of HCl using novel methodology. The in vitro evaluation in HIV p24 assay revealed five potential uracil derivatives with IC50 values ranging from 191.5 μg ml−1 to 62.5 μg ml−1. The meta-chloro substituted uracil compound 9a showed promising activity with an IC50 value of 62.5 μg ml−1 which is well correlated with the computational studies. As expected, all the active compounds were noncytotoxic in BA/F3 and Mo7e cell lines highlighting the thoughtful design. The structure activity relationship indicates the position priority and lower log P values as the possible cause of inhibitory potential of the uracil compounds.
- 26 April 2022
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 10 (21) , 4048-4058
Chitosan with pendant (E)-5-((4-acetylphenyl)diazenyl)-6-aminouracil groups as synergetic antimicrobial agents
Conventional antimicrobial agents are losing the war against drug resistance day-by-day. Chitosan biopolymer is one of the alternative materials that lends itself well to this application by fine-tuning its bioactivity using different pendant groups. Herein, we report the synthesis of novel chitosan with pendant (E)-5-((4-acetylphenyl)diazenyl)-6-aminouracil (APAU) groups by forming Schiff base linkages between chitosan and the pendant groups. These chitosan biopolymers with pendant APAU groups form films superior in thermal stability compared to the neat chitosan. Interestingly, APAU alone was inactive against K. pneumoniae, E. coli, S. aureus, T. rubrum and C. albicans. However, novel chitosan samples were active against S. aureus with an MIC of 390 μg mL−1, half that of plain chitosan at 780 μg mL−1. APAU modified chitosan samples, CA80 and CA100 showed an MIC (against K. pneumoniae and E. coli) of 23.4 μg mL−1, superior to plain chitosan's MIC of 187.5 μg mL−1 and is close to commercial Fluconazole's MIC of 11.7 μg mL−1. The activity of chitosan changes with APAU content and at higher concentrations shows a strong synergetic antimicrobial effect.
- 26 April 2022
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 10 (21) , 4048-4058
Chitosan with pendant (E)-5-((4-acetylphenyl)diazenyl)-6-aminouracil groups as synergetic antimicrobial agents
Conventional antimicrobial agents are losing the war against drug resistance day-by-day. Chitosan biopolymer is one of the alternative materials that lends itself well to this application by fine-tuning its bioactivity using different pendant groups. Herein, we report the synthesis of novel chitosan with pendant (E)-5-((4-acetylphenyl)diazenyl)-6-aminouracil (APAU) groups by forming Schiff base linkages between chitosan and the pendant groups. These chitosan biopolymers with pendant APAU groups form films superior in thermal stability compared to the neat chitosan. Interestingly, APAU alone was inactive against K. pneumoniae, E. coli, S. aureus, T. rubrum and C. albicans. However, novel chitosan samples were active against S. aureus with an MIC of 390 μg mL−1, half that of plain chitosan at 780 μg mL−1. APAU modified chitosan samples, CA80 and CA100 showed an MIC (against K. pneumoniae and E. coli) of 23.4 μg mL−1, superior to plain chitosan's MIC of 187.5 μg mL−1 and is close to commercial Fluconazole's MIC of 11.7 μg mL−1. The activity of chitosan changes with APAU content and at higher concentrations shows a strong synergetic antimicrobial effect.
- Open Access
- 15 March 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (14) , 8771-8782
Acetylene containing 2-(2-hydrazinyl)thiazole derivatives: design, synthesis, and in vitro and in silico evaluation of antimycobacterial activity against Mycobacterium tuberculosis
In an attempt to find novel anti-mycobacterial agents, novel acetylene containing 2-(2-hydrazinyl)thiazole derivatives have been synthesized and evaluated against Mycobacterium tuberculosis .
- 15 March 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (14) , 8771-8782
Open AccessAcetylene containing 2-(2-hydrazinyl)thiazole derivatives: design, synthesis, and in vitro and in silico evaluation of antimycobacterial activity against Mycobacterium tuberculosis
In an attempt to find novel anti-mycobacterial agents, novel acetylene containing 2-(2-hydrazinyl)thiazole derivatives have been synthesized and evaluated against Mycobacterium tuberculosis .
- 1 December 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 207, 112801
Therapeutic potential of uracil and its derivatives in countering pathogenic and physiological disorders
- 1 December 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 207, 112801
Therapeutic potential of uracil and its derivatives in countering pathogenic and physiological disorders
- 1 November 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 886, 173448
In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2
- 1 November 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 886, 173448
In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2
- 1 July 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 198, 112358
Indole chalcones: Design, synthesis, in vitro and in silico evaluation against Mycobacterium tuberculosis
- 1 July 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 198, 112358
Indole chalcones: Design, synthesis, in vitro and in silico evaluation against Mycobacterium tuberculosis